AR106687A1 - PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO - Google Patents
PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICOInfo
- Publication number
- AR106687A1 AR106687A1 ARP160103472A ARP160103472A AR106687A1 AR 106687 A1 AR106687 A1 AR 106687A1 AR P160103472 A ARP160103472 A AR P160103472A AR P160103472 A ARP160103472 A AR P160103472A AR 106687 A1 AR106687 A1 AR 106687A1
- Authority
- AR
- Argentina
- Prior art keywords
- corticosteroid
- dry powder
- formulation
- adrenergic
- polynergic
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 abstract 1
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 abstract 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 abstract 1
- 229960002462 glycopyrronium bromide Drugs 0.000 abstract 1
- 229940125389 long-acting beta agonist Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Formulación en polvo seco para inhalación que comprende una combinación de un anticolinérgico, un agonista del receptor adrenérgico b2 de acción prolongada, y, opcionalmente, un corticosteroide para inhalación, y con un proceso para la preparación de la misma. Reivindicación 6: El proceso de acuerdo con la reivindicación 1 ó 2, en donde el fármaco antimuscarínico es bromuro de glicopirronio, el ICS es dipropionato de beclometasona, el LABA es fumarato de formoterol dihidrato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194661 | 2015-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106687A1 true AR106687A1 (es) | 2018-02-07 |
Family
ID=54548063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103472A AR106687A1 (es) | 2015-11-16 | 2016-11-14 | PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10086003B2 (es) |
| EP (2) | EP3689379B1 (es) |
| JP (1) | JP6942126B2 (es) |
| KR (1) | KR20180082442A (es) |
| CN (1) | CN108348614B (es) |
| AR (1) | AR106687A1 (es) |
| AU (1) | AU2016357988B2 (es) |
| CA (1) | CA3005291C (es) |
| CL (1) | CL2018001297A1 (es) |
| CO (1) | CO2018005139A2 (es) |
| DK (2) | DK3689379T3 (es) |
| EA (1) | EA037346B1 (es) |
| ES (2) | ES2789365T3 (es) |
| GE (1) | GEP20207178B (es) |
| HR (2) | HRP20200571T1 (es) |
| HU (2) | HUE056402T2 (es) |
| IL (1) | IL259327B (es) |
| MA (1) | MA52437A (es) |
| MX (1) | MX377113B (es) |
| MY (1) | MY198321A (es) |
| PE (1) | PE20181377A1 (es) |
| PH (1) | PH12018501023B1 (es) |
| PL (2) | PL3377109T3 (es) |
| PT (2) | PT3689379T (es) |
| SA (1) | SA518391574B1 (es) |
| SG (2) | SG10201912090UA (es) |
| SI (2) | SI3377109T1 (es) |
| TW (1) | TWI729025B (es) |
| UA (1) | UA125173C2 (es) |
| WO (1) | WO2017085007A1 (es) |
| ZA (1) | ZA201803167B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110582269B (zh) * | 2017-05-11 | 2023-02-28 | 奇斯药制品公司 | 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法 |
| KR20220155609A (ko) | 2017-05-11 | 2022-11-23 | 키에시 파르마슈티시 엣스. 피. 에이. | 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법 |
| WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| US11304901B2 (en) * | 2019-08-28 | 2022-04-19 | Anovent Pharmaceutical (U.S.), Llc | Liposome formulation of fluticasone furoate and method of preparation |
| CN116194087B (zh) * | 2020-01-15 | 2025-07-11 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
| CN111467498A (zh) * | 2020-05-14 | 2020-07-31 | 王兆霖 | 药物组合物制剂 |
| CN117064869A (zh) * | 2023-09-27 | 2023-11-17 | 山东京卫制药有限公司 | 一种胶囊型吸入粉雾剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| DE60239639D1 (de) | 2002-07-31 | 2011-05-12 | Chiesi Farma Spa | Pulverinhalator |
| EP1646370A1 (en) * | 2003-07-11 | 2006-04-19 | Glaxo Group Limited | Pharmaceutical formulations |
| GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| KR20130062268A (ko) | 2010-04-21 | 2013-06-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 정전하가 감소된 입자를 제공하는 방법 |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| PT3019153T (pt) * | 2013-07-11 | 2018-12-04 | Chiesi Farm Spa | Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação |
-
2016
- 2016-11-14 HR HRP20200571TT patent/HRP20200571T1/hr unknown
- 2016-11-14 ES ES16801984T patent/ES2789365T3/es active Active
- 2016-11-14 JP JP2018524831A patent/JP6942126B2/ja active Active
- 2016-11-14 PL PL16801984T patent/PL3377109T3/pl unknown
- 2016-11-14 SI SI201630738T patent/SI3377109T1/sl unknown
- 2016-11-14 MX MX2018005979A patent/MX377113B/es active IP Right Grant
- 2016-11-14 AU AU2016357988A patent/AU2016357988B2/en active Active
- 2016-11-14 KR KR1020187013284A patent/KR20180082442A/ko not_active Withdrawn
- 2016-11-14 AR ARP160103472A patent/AR106687A1/es not_active Application Discontinuation
- 2016-11-14 MY MYPI2018000703A patent/MY198321A/en unknown
- 2016-11-14 MA MA052437A patent/MA52437A/fr unknown
- 2016-11-14 PT PT201568151T patent/PT3689379T/pt unknown
- 2016-11-14 PE PE2018000972A patent/PE20181377A1/es unknown
- 2016-11-14 WO PCT/EP2016/077566 patent/WO2017085007A1/en not_active Ceased
- 2016-11-14 TW TW105137047A patent/TWI729025B/zh active
- 2016-11-14 DK DK20156815.1T patent/DK3689379T3/da active
- 2016-11-14 SG SG10201912090UA patent/SG10201912090UA/en unknown
- 2016-11-14 GE GEAP201614782A patent/GEP20207178B/en unknown
- 2016-11-14 PT PT168019842T patent/PT3377109T/pt unknown
- 2016-11-14 ES ES20156815T patent/ES2890409T3/es active Active
- 2016-11-14 HU HUE20156815A patent/HUE056402T2/hu unknown
- 2016-11-14 SI SI201631330T patent/SI3689379T1/sl unknown
- 2016-11-14 EP EP20156815.1A patent/EP3689379B1/en active Active
- 2016-11-14 SG SG11201804048WA patent/SG11201804048WA/en unknown
- 2016-11-14 PL PL20156815T patent/PL3689379T3/pl unknown
- 2016-11-14 HR HRP20211599TT patent/HRP20211599T1/hr unknown
- 2016-11-14 CN CN201680066805.3A patent/CN108348614B/zh active Active
- 2016-11-14 HU HUE16801984A patent/HUE050343T2/hu unknown
- 2016-11-14 EA EA201890967A patent/EA037346B1/ru unknown
- 2016-11-14 DK DK16801984.2T patent/DK3377109T3/da active
- 2016-11-14 EP EP16801984.2A patent/EP3377109B1/en active Active
- 2016-11-14 UA UAA201805272A patent/UA125173C2/uk unknown
- 2016-11-14 CA CA3005291A patent/CA3005291C/en active Active
- 2016-11-15 US US15/351,510 patent/US10086003B2/en active Active
-
2018
- 2018-05-14 ZA ZA2018/03167A patent/ZA201803167B/en unknown
- 2018-05-14 CL CL2018001297A patent/CL2018001297A1/es unknown
- 2018-05-14 IL IL259327A patent/IL259327B/en active IP Right Grant
- 2018-05-14 SA SA518391574A patent/SA518391574B1/ar unknown
- 2018-05-15 PH PH12018501023A patent/PH12018501023B1/en unknown
- 2018-05-16 CO CONC2018/0005139A patent/CO2018005139A2/es unknown
- 2018-08-27 US US16/113,051 patent/US10786451B2/en active Active
-
2020
- 2020-08-06 US US16/986,796 patent/US10959944B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106687A1 (es) | PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO | |
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| MX2017001637A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| MX377377B (es) | Composiciones tópicas para el alivio del dolor, manufactura y uso. | |
| CR20190394A (es) | Compuestos de inhibidores de autotaxina | |
| BR112016013485A2 (pt) | Método para preparar um produto lácteo tendo teor estável de galacto-oligossacarídeo(s) | |
| CL2015000744A1 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer. | |
| CY1124490T1 (el) | Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο | |
| CR20170077A (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| PE20151759A1 (es) | Imidazopiridazinas sustituidas | |
| CO2017008031A2 (es) | Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico | |
| DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
| CL2016002848A1 (es) | Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd | |
| BR112018072113A2 (pt) | excipiente à base de proteínas para ingredientes farmacêuticos ativos | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| AR100784A1 (es) | Micropartículas multicomponentes para usar en una formulación inhalable, proceso para preparar, formulación farmacéutica, inhalador | |
| MX2018014184A (es) | Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. | |
| CL2016001429A1 (es) | Formas polimórficas de un compuesto similar a un esteroide y metodos para la preparación y su uso | |
| PE20170919A1 (es) | Formulacion inhalable | |
| CN302550275S (zh) | 割草机割草刀测试检具 | |
| TR201716155A1 (tr) | Bir beta-2 agonisti ile birlikte bir kortikosteroid içeren farmasötik formülasyon. | |
| CN302518780S (zh) | 灌装机 | |
| CN302061476S (zh) | 药品包装盒(藿香正气合剂) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |